Grifols, S.A. $GRFS Shares Sold by Whitebox Advisors LLC

Whitebox Advisors LLC reduced its position in Grifols, S.A. (NASDAQ:GRFS) by 21.1% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 2,067,798 shares of the biotechnology company’s stock after selling 553,670 shares during the period. Whitebox Advisors LLC’s holdings in Grifols were worth $16,584,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GRFS. Bank of Montreal Can increased its stake in Grifols by 3,205.1% during the third quarter. Bank of Montreal Can now owns 3,013,723 shares of the biotechnology company’s stock worth $30,017,000 after acquiring an additional 2,922,540 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Grifols by 383.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,800,645 shares of the biotechnology company’s stock valued at $27,894,000 after purchasing an additional 2,221,633 shares in the last quarter. Norges Bank acquired a new position in shares of Grifols in the 4th quarter valued at about $18,139,000. Brandes Investment Partners LP grew its holdings in shares of Grifols by 6.3% during the 4th quarter. Brandes Investment Partners LP now owns 30,954,223 shares of the biotechnology company’s stock worth $289,422,000 after purchasing an additional 1,838,727 shares during the period. Finally, Barclays PLC grew its holdings in shares of Grifols by 132.6% during the 4th quarter. Barclays PLC now owns 2,434,636 shares of the biotechnology company’s stock worth $22,764,000 after purchasing an additional 1,387,783 shares during the period.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wall Street Zen lowered shares of Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Zacks Research upgraded shares of Grifols from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Weiss Ratings lowered shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Grifols currently has a consensus rating of “Reduce” and a consensus price target of $10.00.

Grifols Stock Performance

Shares of GRFS opened at $7.58 on Monday. Grifols, S.A. has a 12 month low of $6.96 and a 12 month high of $11.14. The stock’s 50-day moving average is $7.51 and its two-hundred day moving average is $8.21. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.47 and a quick ratio of 0.85. The stock has a market cap of $5.16 billion, a PE ratio of 39.89, a P/E/G ratio of 0.29 and a beta of 0.67.

Grifols Announces Dividend

The business also recently declared a special dividend, which was paid on Thursday, July 9th. Investors of record on Thursday, July 2nd were given a dividend of $0.0945 per share. The ex-dividend date of this dividend was Thursday, July 2nd. Grifols’s payout ratio is 121.05%.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.